北京商报讯（记者 李海媛）5月23日，深交所发布关于对国泰海通证券股份有限公司（以下简称"国泰海通"）及相 关当事人给予纪律处分的决定。 深交所指出，2023年5月8日，受理了中鼎恒盛气体设备（芜湖）股份有限公司（以下简称"发行人"）首次公开发行 股票并在创业板上市的申请。项目保荐人原为国泰君安证券股份有限公司（以下简称"国泰君安"），因国泰君安吸 收合并海通证券股份有限公司，更名为国泰海通，贾超、陈金科为项目保荐代表人。经查明，国泰海通、贾超、陈 金科在执业过程中存在违规行为。 深交所提到，国泰海通、贾超、陈金科在执业过程中存在未充分关注发行人存在的重大内部控制缺陷，未对发行人 财务信息的可靠性予以审慎核查，发表的核查意见不准；未充分核查发行人研发费用内部控制的有效性，发表的核 查意见不准确；未充分关注发行人收入确认存在的不规范情形，发表的核查意见不准确；对发行人实际控制人资金 占用流向以及关键岗位人员的资金流水核查不到位；未督促发行人及时披露对赌协议的特殊权利条款。 深交所表示，内部控制健全有效是首次公开发行股票的发行条件，发行人未披露其在报告期内进行理账且理账前后 财务数据差异较大，会计基础薄弱、内部控 ...

Group 1 - The core viewpoint is that the valuation enhancement logic of the gold and jewelry industry will continue to unfold in 2024, as the industry enters a phase of clearing and upgrading [1] - Leading companies are shifting from store expansion strategies to improving efficiency at individual stores, forming a synergy with franchisees to promote high-margin products [1] - Differentiated products are driving gold and jewelry companies to transition from "channel brands" to "consumer brands," indicating a strong focus on product strength and the ability to capture consumer demand [1]

国泰海通证券股份有限公司 关于无锡芯朋微电子股份有限公司 关于差异化权益分派特殊除权除息的核查意见 国泰海通证券股份有限公司（以下简称"保荐人"、"国泰海通"）作为正在 履行无锡芯朋微电子股份有限公司（以下简称"芯朋微"、"公司"）持续督导工 作的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》 根据《上市公司股份回购规则》等有关规定，上市公司回购专用证券账户中 的股份，不享有利润分配、公积金转增股本的权利。因此，公司回购专用证券账 户中的股份将不参与公司本次利润分配、公积金转增股本，故申请 2024 年度权 益分配实施差异化权益分派。具体情况如下： 一、差异化分红的原因 以集中竞价交易方式回购公司股份方案的议案》，同意公司以超募资金通过上海 证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股 股票。回购的股份将在未来适宜时机全部用于员工持股计划或股权激励，回购价 格不超过 151.70 元/股（含），回购资金总额不低于人民币 5,500 万元（含），不 超过人民币 11,000 万元（含），回购期限自公司董事会审议通过本次回购方案之 日起 6 个月内。截至 ...

Core Insights - The overall sensitivity of deposit scale to the reduction of deposit rates is low, indicating a strong willingness among individuals and businesses to allocate funds to bank deposits despite rate cuts [1][10] - The shift of deposits from the banking system to asset management products is primarily attributed to the manual interest compensation rectification in April 2024, which had a short-term impact but began to stabilize by July of the same year [1][10] - The proportion of personal and corporate deposits in the broad money supply has increased from approximately 48% to 52% by March 2024, reflecting a robust demand for bank deposits [1][10] Deposit Rate Adjustments - The reduction in deposit rates in July and October 2024 led to a noticeable decline in the year-on-year growth of large bank deposits, dropping from 5.8 trillion yuan to 5.2 trillion yuan and from 5.0 trillion yuan to 4.8 trillion yuan respectively [3] - The asset management product scale saw a rebound, with a shift from a year-on-year decrease of 629.5 billion yuan in August 2024 to a slight increase of 10 billion yuan, and a similar trend was observed in November 2024 [3] Deposit Growth Trends - Large banks' personal and corporate deposit year-on-year growth fluctuated, with notable increases and decreases observed in various months, indicating a dynamic response to interest rate changes [5] - The year-on-year growth of deposits in small and medium-sized banks also showed variability, with a peak growth of 81.56 billion yuan followed by a decrease of 25.29 billion yuan [5] Market Reactions - The bond market typically reacts in advance to expectations of deposit rate cuts, with rates generally declining before the official announcement, although the actual impact on market trends remains limited [10] - Following the last three deposit rate cuts, the yields on various bonds, including government bonds and credit bonds, generally trended downward over the subsequent trading days [10] Future Outlook - The current round of deposit rate cuts is expected to have a limited impact on the outflow of funds, with the probability of a return to a tight liquidity situation similar to the first quarter of the year being low [10] - The attractiveness of asset management products is anticipated to decrease due to ongoing adjustments in performance benchmarks, which may lead to a shift of funds back to deposits [10]

Group 1 - The event "Rational Investment Companion" focused on the company Zhifei Biological Products Co., Ltd. (300122), which is a component of the ChiNext 50 Index, aimed at enhancing investor services and promoting investment quality [2][3] - Zhifei Biological, established in 2002, is a comprehensive biopharmaceutical company engaged in the research, production, sales, and distribution of vaccines and biological products, and was the first private vaccine company listed on the ChiNext in September 2010 [3][4] - The company’s main products include various vaccines such as recombinant COVID-19 protein vaccine, tuberculosis vaccines, and meningococcal polysaccharide vaccines, with a recent collaboration with GSK for the exclusive distribution of a recombinant shingles vaccine [4][5] Group 2 - The event agenda includes a tour of Zhifei Biological's exhibition hall, an introduction to the Shenzhen Stock Exchange, sharing of ETF investment strategies, discussion on index investment value, and interactive communication with investors [4][6] - The company operates under the mission of "preventing diseases before they occur and treating existing diseases," aiming to build a world-class biopharmaceutical enterprise [3][4]

Core Viewpoint - The report outlines the continuous sponsorship and supervision activities conducted by Guotai Junan Securities for Shaanxi Sry New Materials Co., Ltd. following its IPO, emphasizing compliance with regulations and the company's operational performance. Group 1: Continuous Supervision Activities - The company issued 40.01 million shares at a price of RMB 10.48 per share, raising a total of RMB 419.30 million, with a net amount of RMB 356.91 million after deducting issuance costs [1]. - Guotai Junan Securities has been appointed as the continuous sponsor from March 16, 2022, to December 31, 2025, conducting regular communications, site inspections, and due diligence [1][2]. - The sponsor has assisted the company in establishing internal systems and decision-making processes to comply with legal and regulatory requirements [1][2]. Group 2: Information Disclosure and Compliance - The sponsor reviewed the company's information disclosure documents, ensuring compliance with relevant regulations and confirming that disclosures were accurate and timely [9]. - During the supervision period, the company and its major stakeholders did not fail to fulfill any commitments [2][6]. - The company has been advised to maintain transparency and avoid concealing important information [1][2]. Group 3: Financial Performance and Key Indicators - The company's revenue for 2024 is reported at approximately RMB 1.33 billion, reflecting a 12.73% increase from the previous year [20]. - The net profit attributable to shareholders increased by 26.88%, driven by revenue growth and improved sales structure [22]. - The company's total assets reached approximately RMB 2.13 billion, marking a 24.39% increase compared to the previous year [20]. Group 4: Research and Development - The company invested RMB 68.83 million in R&D, representing 5.18% of its revenue, which is an increase from 5.04% in the previous year [22]. - The company has developed new products and technologies, including high-performance copper alloys for liquid rocket engines and components [22][24]. - The R&D team, led by nine core technical personnel, has established partnerships with aerospace institutions to enhance technological capabilities [11][22]. Group 5: Market Risks and Challenges - The company faces risks related to technological advancements in the new materials industry, which require continuous R&D investment to maintain competitive advantages [10][17]. - Potential market disruptions may arise from the introduction of new materials and technologies that could replace existing products [17][18]. - The company is also exposed to risks from fluctuations in raw material prices, particularly copper, which significantly impacts production costs [14][16].

国泰海通证券股份有限公司 关于用友汽车信息科技（上海）股份有限公司 差异化权益分派特殊除权除息事项的核查意见 《上海证券交易所科创板股票上公规则》 《上海证券交 （ 易所上公公司自律监管指引第 11 号——持续督导》 《上海证券交易所科创板上公 （ 公司自律监管指引第 7 号——回购股份》等有关法律、法规的规定，对友车科技 差异化权益分派特殊除权除息事项进行了审慎核查，具体情况如下： 一、本次差异化权益分派的原因 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"）作为用友 汽车信息科技（上海）股份有限公司（ （以下简称（ "公司"、 "（ 上公公司"、 "友车科 技"）首次公开发行股票并在科创板上公持续督导工作的保荐人，根据《证券发 行上公保荐业务管理办法》 根据公司 2024 年年度股东大会审议通过的《关于 2024 年度利润分配预案的 议案》，公司拟向全体股东每 10 股派发现金红利 5.00 元（含税），不送红股，不 进行资本公积转增股本。公司通过回购专用账户所持有的本公司股份不参与本次 利润分配。截至 2025 年 3 月 27 日，公司总股本 144,317,400 股，扣除回购专用 证券 ...

Core Viewpoint - The company, Maiwei (Shanghai) Biotechnology Co., Ltd., has faced challenges in its product sales, particularly with its flagship products, Kunmaikang and Maiweijian, due to market competition and regulatory hurdles, but is implementing strategic adjustments to improve performance and expand market access [1][2][4]. Group 1: Company Performance - In 2024, the company achieved a revenue of 200 million RMB, a year-on-year increase, but faced a significant decline in the shipment of Kunmaikang, which dropped by 66.61% to 48,821 units [1][2]. - The sales revenue for Maiweijian reached 14,459.20 million RMB in 2024, with a gross profit margin of 82.89% [2][3]. - The overall gross profit for the company increased from 4,075.41 million RMB in 2023 to 11,984.65 million RMB in 2024, with a gross profit margin decrease from 96.83% to 82.89% [3][4]. Group 2: Product Analysis - Kunmaikang, a biosimilar to Humira, has seen a decline in shipment volume due to intense market competition and regulatory challenges, with eight similar products already approved in China [5][6]. - Maiweijian, a biosimilar to Xgeva, has been gradually gaining market access, with 75 hospitals approved by the end of 2024, but its market entry has been slower compared to the original drug [10][11]. - The company plans to expand the indications for Maiweijian to include SREs, which could enhance its market potential [12][20]. Group 3: Strategic Adjustments - The company is optimizing its regional operational model to improve efficiency and resource allocation, transitioning from self-operated sales to cooperative models in underperforming areas [8][9]. - A focus on enhancing marketing strategies and academic promotion is underway to improve brand recognition and market penetration for Kunmaikang [9][10]. - The company is actively pursuing international collaborations and expanding its product pipeline, with several products in advanced clinical stages expected to launch in the next few years [21][22][23].

国泰海通证券研报表示，延续前期观点，白酒行业2025年第二季度产业景气度环比角度仍在寻底，价格 端压力大于量的压力，从库存周期视角看，白酒产业或完全进入到库存周期后半段，在此维度下，大部 分企业短期业绩表现愈发赖于核心市场的市占率提升，且愈发依赖于腰部及以下单品驱动，份额逻辑演 绎到最后阶段。白酒商品属性正在加速重塑，其快消品属性强化，能够提前适应快消品运作逻辑的企业 竞争优势会愈发凸显。股价层面，白酒板块配置价值凸显：1)分红层面有潜力：当下头部企业股息率接 近或大于3%；2)动态估值基本回落至历史区间低位；3)后续具备潜在催化因素，例如房价等资产价格边 际企稳，内需政策等；4)选股层面，首选具备份额逻辑的企业。 ...

Core Viewpoint - The aerospace industry in China is experiencing unprecedented development opportunities driven by strong demand growth and accelerated innovation, with the market size expected to exceed 2 trillion yuan by 2024 [1] Group 1: Industry Growth and Demand - The aerospace industry is positioned as a strategic foundation for national security amid global geopolitical tensions, with China's defense budget projected to reach 1.81 trillion yuan by 2025, maintaining a growth rate of 7.2% for three consecutive years [1] - Key growth engines in the aerospace sector include commercial aerospace, commercial aircraft, and low-altitude fields, reflecting a robust demand landscape [1] - The demand side is characterized by the upgrading of defense equipment, the rise of emerging fields, and the expansion of global markets, all contributing to strong demand [1] Group 2: Supply Side Transformation - The supply side is undergoing profound changes with accelerated breakthroughs in technological self-innovation, continuous policy benefits, and enhanced collaborative effects within the industry chain [1] - The interaction between supply and demand is fostering a new landscape for high-quality development in the industry, significantly improving efficiency and competitiveness [1] Group 3: Investment Opportunities - The aerospace industry presents long-term value opportunities for the capital market, driven by technological breakthroughs and policy support, leading to significant characteristics such as industry chain collaboration, market demand expansion, and efficiency improvements [2] - Military state-owned enterprises are enhancing asset securitization rates through reforms, while private companies focus on flexible manufacturing and commercial aerospace, rapidly capturing market share in niche areas [2] - The dual-use technology transformation is creating new growth points, with military technologies extending into sectors like new energy vehicles and high-end equipment, broadening application spaces [2] - As the global aerospace industry enters a new expansion cycle, China's industry penetration and added value are expected to continue rising, with a focus on leading enterprises that have deep technological moats and clear capacity releases [2]